CN104933313A - Quantitative evaluation system of radio-chemotherapy specification conformity for malignant tumors - Google Patents
Quantitative evaluation system of radio-chemotherapy specification conformity for malignant tumors Download PDFInfo
- Publication number
- CN104933313A CN104933313A CN201510364527.7A CN201510364527A CN104933313A CN 104933313 A CN104933313 A CN 104933313A CN 201510364527 A CN201510364527 A CN 201510364527A CN 104933313 A CN104933313 A CN 104933313A
- Authority
- CN
- China
- Prior art keywords
- quantitative evaluation
- case
- stocking
- microprocessor
- conformity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a quantitative evaluation system of a radio-chemotherapy specification conformity for malignant tumors. The quantitative evaluation system of the radio-chemotherapy specification conformity for malignant tumors comprises a microprocessor; the system further comprises an input system, a storage system and a comparison system, wherein the input system, the storage system and the comparison system are simultaneously connected with the microprocessor. According to the invention, the quantitative evaluation system of the radio-chemotherapy specification conformity for malignant tumors not only can reduce the duplication of labor, improve the working efficiency, save the investment, but also can fast and effectively carry out the quantitative evaluation and achieve reliability and integrity; the system further can fast and effectively solve the actual problems through a help system which can be connected with an expert, thereby fast ensuring the patient safety.
Description
Technical field
The present invention is specifically related to a kind of quantitative evaluation system of concurrent chemoradiotherapy of malignant tumor specification degree of conformity.
Background technology
At present, cancer has become the first killer of health of people.And the level of present stage oncotherapy is not high limited, but its methods for the treatment of is more, and curative effect differs.Especially and oncotherapy is also a quite long process, so especially for the patient of middle and advanced stage, more need to also have the multiple treatment meanss such as biological therapy to cooperatively interact operation, chemicotherapy, radiotherapy, targeted drug, just can obtain good therapeutic effect.
But China of China also exists sizable randomness and lack of standard in oncotherapy, many patients are after being made a definite diagnosis, detour has been walked because therapeutic scheme is incorrect, chemicotherapy lack of standardization, not only increase the weight of the financial burden of patient, also delayed best occasion for the treatment, accelerate death even on the contrary, so it may be necessary very much technological means to carry out the treatment of specification degree of conformity, improve therapeutic process curative effect to monitor.5 years survival rates of all tumor patients of the U.S. reach 68%, and China only 25%, topmost reason is the non-standard degree of conformity of oncotherapy, and China News Service reports, the tumor patient of China 15% is because treatment accelerations death lack of standardization.The non-standard degree of conformity of oncotherapy is especially serious to middle and small hospital.
China's tumor diagnosis and treatment existing problems have a lot, be the most seriously wherein problem be overmedication or deficiency, as extended the chemicotherapy cycle, blindly adding medicine, excessive radiation therapy, ignore pharmacokinetic data, the best opportunity of chemicotherapy may be caused at this point to miss.It two is excessively pursue new technology, abuses the clinical means of immature or non-adaptive disease, or arbitrarily uses supplemental treatment.It three is despise the multidisciplinary consultation of doctors, often gives patient unilateral treatment from branch, and the tumor diagnosis and treatment guide of the cancer clinical diagnosis and treatment specification of US National comprehensive cancer Web Publishing, China all gives diagnoses and treatment flow and scheme from multidisciplinary angle.
Current China also exists sizable randomness and lack of standard in tumor pharmacother, and many patients, after being made a definite diagnosis, have walked detour because therapeutic scheme is unreasonable.Such as, after colorectal cancer operation in patients chemoradiation therapy, Irinotecan has been proved the chemoradiation therapy that can not be used for this kind of illness, and part doctor is because be unfamiliar with medicine, employs Irinotecan to patient.For another example target therapeutic agent carries out some gene appearance before using in advance, as Victibix or Cetuximab need to detect K-Ras detection in Gene Mutation, to K-Ras wild type Patients with Colorectal Cancer just recommendation Victibix or Cetuximab.Tarceva or Gefitinib need to carry out EGFR genetic mutation detection, are detected as saltant type patient and just possess good RR.
Chemoradiotherapy standard conformity is exactly cancer clinical diagnosis and treatment specification and the chemicotherapy drug data bank of the comprehensive cancer Web Publishing of foundation US National, chemicotherapy process is monitored, go to measure and service quality and the result for the treatment of of evaluating chemicotherapy process according to standard, allow therapeutic process meet specification.The formulation of the cancer clinical diagnosis and treatment specification of the comprehensive cancer Web Publishing of tumor diagnosis and treatment guide US National, the technology accumulation having it thick and heavy, its organizational structure is complete, specialist crew's coverage rate is extensive, and relate to field section office many, clinical time is experienced, formulation content is comprehensive, through deliberating repeatedly, following card according to constantly updating according to the best, and being issued by authority.
Because comprehensive, preciseness, the logicality of guide are strong, there is the specification of operation can foundation, be therefore used widely in tumor diagnosis and treatment.And hospital of China may not operate with operationally meeting specification, therefore need the standardization level of enforcement implementing tumor diagnosis and treatment, patient is benefited.
Diagnosis and treatment specification is in continuous progress, and new clinical means is also in continuous renewal, and basic unit doctor often can not read documents in time, and therefore diagnosis and treatment specification is extremely huge to the directive function of basic unit doctor.In such a case, specification degree of conformity how is implemented the most urgent.Need specification to do a criterion, quantitative evaluation is carried out to medical institutions at different levels, improve the randomness of medical institutions and doctor, reduce dangerous generation.But, although have the data such as the indication of specification, drug data bank, clinical laboratory data and diagnosis and treatment means at present, still lack one to the evaluating system of the chemoradiotherapy standard conformity degree meeting specification to quantitatively evaluating medical institutions and doctor's diagnosis and treatment.If specification degree of conformity cannot quantize, be then difficult to carry out specification evaluation effectively to a diagnosis and treatment case, also effectively cannot promote that clinician meets dynamics to specification.
Summary of the invention
In order to solve the problems of the technologies described above, the invention provides a kind of quantitative evaluation system of concurrent chemoradiotherapy of malignant tumor specification degree of conformity, not only can reduce the duplication of labour, improve work efficiency, investment reduction, and carry out quantitative evaluation fast and effectively, reliably just, simultaneously by with help system can with expert's line, solve the actual difficulty run into fast and effectively, the safety of patient can be ensured fast.
A quantitative evaluation system for concurrent chemoradiotherapy of malignant tumor specification degree of conformity, comprises microprocessor, and it also comprises input system, stocking system and Compare System.Described input system, stocking system are connected with microprocessor with Compare System simultaneously.
The parameter of concurrent chemoradiotherapy of malignant tumor is mainly directly inputted in system by described input system, is directly sent to microprocessor via input system, also the method for chemicotherapy is inputed to microprocessor simultaneously simultaneously.
Described stocking system mainly stores draws together concurrent chemoradiotherapy of malignant tumor diagnosis and treatment normative database, medicine knowledge base and case database; Described stocking system also comprises wireless receiver, can by the relevant case data of collection all parts of the world, internet.
Described Compare System mainly selects the most close case in stocking system, the case of this case and input end is compared simultaneously, obtains a quantitative evaluation; If do not find in stocking system, then by the wireless receiver of stocking system, carry out similar case by internet and choose and comparison, obtain quantitative evaluation.
Described quantitative evaluation system also comprises help system, and described help system is connected with external experts, can when similar case cannot be obtained by stocking system and internet and this domain expert inquire into, and obtain the quantitative evaluation of notarization relatively.
Compared with prior art, the present invention has following beneficial effect:
The invention provides a kind of quantitative evaluation system of concurrent chemoradiotherapy of malignant tumor specification degree of conformity, not only can reduce the duplication of labour, improve work efficiency, investment reduction, and carry out quantitative evaluation fast and effectively, reliably just, simultaneously by with help system can with expert's line, solve the actual difficulty run into fast and effectively, the safety of patient can be ensured fast
Accompanying drawing explanation
Fig. 1 is schematic diagram of the present invention.
Embodiment
Below in conjunction with embodiment, the present invention is described further:
Embodiment
A quantitative evaluation system for concurrent chemoradiotherapy of malignant tumor specification degree of conformity, comprises microprocessor, and it also comprises input system, stocking system and Compare System.Described input system, stocking system are connected with microprocessor with Compare System simultaneously.
The parameter of concurrent chemoradiotherapy of malignant tumor is mainly directly inputted in system by described input system, is directly sent to microprocessor via input system, also the method for chemicotherapy is inputed to microprocessor simultaneously simultaneously.
Described stocking system mainly stores draws together concurrent chemoradiotherapy of malignant tumor diagnosis and treatment normative database, medicine knowledge base and case database; Described stocking system also comprises wireless receiver, can by the relevant case data of collection all parts of the world, internet.
Described Compare System mainly selects the most close case in stocking system, the case of this case and input end is compared simultaneously, obtains a quantitative evaluation; If do not find in stocking system, then by the wireless receiver of stocking system, carry out similar case by internet and choose and comparison, obtain quantitative evaluation.
Described quantitative evaluation system also comprises help system, and described help system is connected with external experts, can when similar case cannot be obtained by stocking system and internet and this domain expert inquire into, and obtain the quantitative evaluation of notarization relatively.
The invention provides a kind of quantitative evaluation system of concurrent chemoradiotherapy of malignant tumor specification degree of conformity, not only can reduce the duplication of labour, improve work efficiency, investment reduction, and carry out quantitative evaluation fast and effectively, reliably just, simultaneously by with help system can with expert's line, solve the actual difficulty run into fast and effectively, the safety of patient can be ensured fast.
The foregoing is only some embodiments of the present invention, do not limit the present invention, the technical scheme that the mode that all employings are equal to replacement or equivalent transformation obtains, all drop in protection scope of the present invention.
Claims (2)
1. the quantitative evaluation system of a concurrent chemoradiotherapy of malignant tumor specification degree of conformity, comprise microprocessor, it also comprises input system, stocking system and Compare System, it is characterized in that, described input system, stocking system is connected with microprocessor with Compare System simultaneously, the parameter of concurrent chemoradiotherapy of malignant tumor is mainly directly inputted in system by described input system, directly microprocessor is sent to via input system, also the method for chemicotherapy is inputed to microprocessor simultaneously simultaneously, described stocking system mainly stores draws together concurrent chemoradiotherapy of malignant tumor diagnosis and treatment normative database, medicine knowledge base and case database, described stocking system also comprises wireless receiver, can by the relevant case data of collection all parts of the world, internet, described Compare System mainly selects the most close case in stocking system, the case of this case and input end is compared simultaneously, obtains a quantitative evaluation, if do not find in stocking system, then by the wireless receiver of stocking system, carry out similar case by internet and choose and comparison, obtain quantitative evaluation.
2. the quantitative evaluation system of a kind of concurrent chemoradiotherapy of malignant tumor specification degree of conformity according to claim 1, it is characterized in that, described quantitative evaluation system also comprises help system, described help system is connected with external experts, can when similar case cannot be obtained by stocking system and internet and this domain expert inquire into, and obtain the quantitative evaluation of notarization relatively.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510364527.7A CN104933313A (en) | 2015-06-29 | 2015-06-29 | Quantitative evaluation system of radio-chemotherapy specification conformity for malignant tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510364527.7A CN104933313A (en) | 2015-06-29 | 2015-06-29 | Quantitative evaluation system of radio-chemotherapy specification conformity for malignant tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104933313A true CN104933313A (en) | 2015-09-23 |
Family
ID=54120478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510364527.7A Pending CN104933313A (en) | 2015-06-29 | 2015-06-29 | Quantitative evaluation system of radio-chemotherapy specification conformity for malignant tumors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104933313A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060227803A1 (en) * | 2002-05-21 | 2006-10-12 | Bellsouth Intellectual Property Corporation | Temporary Contact Alias System |
| CN103268412A (en) * | 2013-05-20 | 2013-08-28 | 浙江大学 | Multiple primary malignant tumor chemoradiotherapy standard conformity assessment method |
| CN103279668A (en) * | 2013-05-31 | 2013-09-04 | 浙江大学 | Quantitative evaluation system for cancer chemoradiotherapy standard conformity |
| CN103279660A (en) * | 2013-05-23 | 2013-09-04 | 浙江大学 | Chemoradiotherapy standardized cloud center system |
| CN103294908A (en) * | 2013-05-20 | 2013-09-11 | 浙江大学 | Cloud-computing-based method for evaluating malignant tumor chemoradiotherapy standard execution level |
-
2015
- 2015-06-29 CN CN201510364527.7A patent/CN104933313A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060227803A1 (en) * | 2002-05-21 | 2006-10-12 | Bellsouth Intellectual Property Corporation | Temporary Contact Alias System |
| CN103268412A (en) * | 2013-05-20 | 2013-08-28 | 浙江大学 | Multiple primary malignant tumor chemoradiotherapy standard conformity assessment method |
| CN103294908A (en) * | 2013-05-20 | 2013-09-11 | 浙江大学 | Cloud-computing-based method for evaluating malignant tumor chemoradiotherapy standard execution level |
| CN103279660A (en) * | 2013-05-23 | 2013-09-04 | 浙江大学 | Chemoradiotherapy standardized cloud center system |
| CN103279668A (en) * | 2013-05-31 | 2013-09-04 | 浙江大学 | Quantitative evaluation system for cancer chemoradiotherapy standard conformity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahmed et al. | Radiosensitivity of lung metastases by primary histology and implications for stereotactic body radiation therapy using the genomically adjusted radiation dose | |
| US20180039726A1 (en) | Computer based system for predicting treatment outcomes | |
| Heron et al. | Single-session and multisession CyberKnife radiosurgery for spine metastases—University of Pittsburgh and Georgetown University experience | |
| Tang et al. | Creation of a prognostic index for spine metastasis to stratify survival in patients treated with spinal stereotactic radiosurgery: secondary analysis of mature prospective trials | |
| Krummel et al. | Impact of sequencing radiation therapy and immune checkpoint inhibitors in the treatment of melanoma brain metastases | |
| CN103279668B (en) | A kind of quantitative evaluation system of concurrent chemoradiotherapy of malignant tumor specification degree of conformity | |
| De et al. | Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation | |
| De et al. | Radiation-associated lymphopenia and outcomes of patients with unresectable hepatocellular carcinoma treated with radiotherapy | |
| Esagian et al. | Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes | |
| Liu et al. | Icotinib as adjuvant treatment for stage II-IIIA lung adenocarcinoma patients with EGFR mutation (ICWIP study): study protocol for a randomised controlled trial | |
| CN113628761A (en) | Prediction method for treatment efficacy of anti-angiogenesis drug combined with immune checkpoint inhibitor | |
| Sellers et al. | Patient‐reported outcome measures in metastatic prostate cancer | |
| Olsen et al. | Trends in conditional survival and predictors of late death in neuroblastoma | |
| Estevez‐Ordonez et al. | Racial and socioeconomic disparities in glioblastoma outcomes: A single‐center, retrospective cohort study | |
| CN104933313A (en) | Quantitative evaluation system of radio-chemotherapy specification conformity for malignant tumors | |
| He et al. | Lung immune prognostic index could predict metastasis in patients with osteosarcoma | |
| Sequist et al. | A new BATTLE in the evolving war on cancer | |
| Benzekry et al. | Mechanistic modeling of brain metastases in NSCLC provides computational markers for personalized prediction of outcome | |
| Boncz et al. | Health insurance treatment cost of colorectal cancer in Hungary | |
| Majem et al. | Understanding health-related quality of life measures used in early-stage non-small cell lung cancer clinical trials: A review | |
| Reyes et al. | Costs associated with second-line therapies for lung cancer | |
| Wojtukiewicz et al. | Clinical practice in secondary prophylaxis and management of febrile neutropenia in Poland: results of the febrile neutropenia awareness project | |
| Yoo et al. | Economic burden of hysterectomies in the United States: incremental effects in cancer patients | |
| Qi et al. | Competing Risk Nomogram to Predict Cancer-Specific Survival in Esophageal Cancer Patients During the Intensity-Modulated Radiation Therapy Era: A Single Institute Analysis | |
| Rathore et al. | Imaging phenotypes predict overall survival in glioma more accurate than basic demographic and cell mutation profiles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Xu Haiping Document name: Notification of Passing Examination on Formalities |
|
| DD01 | Delivery of document by public notice | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150923 |
|
| WD01 | Invention patent application deemed withdrawn after publication |